Special lssues

Biomarkers in Glioblastoma: Application of Systems Biology

Submission Deadline: 28 February 2023 (closed)

Guest Editors

Dinh-Toi Chu, Faculty of Applied Sciences, International School, Vietnam National University, Vietnam. Email: toicd@vnu.edu.vn
Jian Xu, Chongqing precision medical industry technology research institute, China. Email: jimxj@foxmail.com
Liu Zhijun, Tongji Medical College, Huazhong University of science and technology, China. Email: zhijunliu2@outlook.com
Luo Shengjun, Chongqing Medical University, China. Email: luosheng0618@foxmail.com


Glioblastoma is the most common and aggressive primary brain tumor in adults. Defining histopathologic features are necrosis and endothelial proliferation, resulting in the assignment of grade IV, the highest grade in the World Health Organization (WHO) classification of brain tumors. Despite advances in surgical resection, radiotherapy and chemotherapy, prognosis remains very poor.


Over the last years, due to the development of high-throughput molecular biology technology, major advances have been accomplished in the molecular characterization of glioblastoma. For example, studies have shown that Marco and EGFR can be used as clinical markers in glioblastoma, and STAT3 can be used as therapeutic targets for glioblastoma. And miRNA-profiling studies in glioblastoma patients have found that aberrant miRNA expression can be used as a target for developing new biomarkers for disease detection and for determining prognosis or therapeutic response. A growing number of studies are looking for new biomarkers in Glioblastoma, which will play an important role in disease progression and prognosis, and as potential therapeutic targets.


This special issue welcomes original research articles as well as comprehensive reviews about all topics related to the combination of bioinformation and glioblastoma. Such as the discovery of new biomarkers or targets, the introduction of new targeted treatments and immunotherapies in the clinic, new strategies to deal with drug resistance and relapsed disease, and emerging areas, such as issues associated with tumor microenvironment.


Glioblastoma; Biomarkers; molecular level; targeted therapy; precision medicine; systems biology

Share Link